Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
On September 9, 2015, Cambridge, Massachusetts, USA, and Osaka, Japan, announced that the U.S. Food and Drug Administration (FDA) had granted priority review status to the New Drug···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：301
The U.S. Food and Drug Administration (FDA) approved ixazomib today for use in combination with two other therapies to treat patients with multiple myeloma who have received at lea···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：311
Ivosidenib is available only with a doctor's prescription.Important Precautions for Ivosidenib UseIf you experience any changes in heart rhythm, contact your doctor immediately···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：388
KRAS G12C mutation in non-small cell lung cancer and colorectal cancer【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：184
Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：214
Non-small cell lung cancer【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：230
Gilteritinib is suitable for Leukemia.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：216
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：339
Treatment of refractory relapsed multiple myeloma and certain types of diffuse large B-cell lymphoma.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：289
It is indicated for patients with susceptible isocitrate dehydrogenase-1 (IDH1) mutations confirmed by a test method approved by the FDA.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：260
Exkivity is suitable for specific non-small cell lung cancer(NSCLC).【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：267
Broad-spectrum antitumor agents【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：177
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：8552025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：10562024-09-07
Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding cou···【more】
Recommended：3472026-10-10
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended：4202026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended：6192026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended：6062026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended：4752026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended：6232026-31-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
